

Immune Targeting in Breast Cancer

Ashley Cimino-Mathews, MD

International Society of Breast Pathology Companion Meeting, USCAP 2017

References/Suggested Reading:

1. Adams S, Goldstein LJ, Sparano JA, Demaria S, Badve SS. Tumor infiltrating lymphocytes (TILs) improve prognosis in patients with triple negative breast cancer (TNBC). *Oncoimmunology*. 2015 Jul 27;4(9):e985930.
2. Adams S, Gray RJ, Demaria S, et al. Prognostic value of tumor-infiltrating lymphocytes in triple negative breast cancers from two Phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. *J Clin Oncol*, 2014; 32:2959-67.
3. Adams S. Enlisting the Immune System to Cure Breast Cancer--A Recipe for Success. *JAMA Oncol*. 2016 Jan;2(1):25-7.
4. Bates GJ, Fox SB, Han C, et al. Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. *J Clin Oncol*, 2006; 24:5373-80.
5. Cimino-Mathews A, Foote JB, Emens LA. Immune targeting in breast cancer. *Oncology (Williston Park)*. 2015 May;29(5):375-85
6. Cimino-Mathews A, Hicks JL, Sharma R, et al. Metastatic breast cancers at first relapse have fewer tumor-infiltrating lymphocytes than their matched primary breast tumors: a pilot study. *Human Pathol*, 2013; 44: 2494-500.
7. Cimino-Mathews A, Thompson E, Taube JM, et al. PD-L1 (B7-H1) expression and the immune tumor microenvironment in primary and metastatic breast carcinomas. *Hum Pathol*. 2016 Jan;47(1):52-63.
8. Denkert C, Loibl S, Noske A, et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. *J Clin Oncol*, 2010; 28:105-13.
9. Denkert C, von Minckwitz G, Brase JC, et al. Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers. *J Clin Oncol*. 2015;33:983-91
10. Desmedt C, Haibe-Kains B, Wirapati P, et al. Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. *Clin Cancer Res*, 2008; 15:5158-65.
11. Dieci MV, Cristicello C, Goubar A, et al. Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple negative breast cancer: a retrospective multicenter study. *Ann Oncol*, 2014; 25:611-8.
12. Dunn GP, Bruce AT, Ikeda H, et al. Cancer immunoediting: from immunosurveillance to tumor escape. *Nat Immunol*, 2002; 3:991-8.
13. Emens L, Braiteh F, Cassier P, et al. Inhibition of PD-L1 by MPDL3280A leads to clinical activity in patients with metastatic triple negative breast cancer. Paper presented at: 2014 San Antonio Breast Cancer Symposium; 2014 December 9-13, San Antonio, Texas.
14. Emens LA. Breast cancer immunobiology driving immunotherapy: vaccines and immune checkpoint blockade. *Expert Rev Anticancer Ther*, 2012; 12:1597-1611.
15. Fridman WH, Pages F, Sautes-Fridman, Galon J. The immune contexture in human tumours: impact on clinical outcome. *Nature Rev Cancer*, 2012; 12:298-306.

16. Gajewski TJ, Schreiber H, Fu YX. Innate and adaptive cells in the tumor microenvironment. *Nature Immunol*, 2013; 14:1014-22.
17. Galon J, Mlecnik B, Bindea G, et al. Towards the introduction of the 'Immunoscore' in the classification of malignant tumours. *J Pathol*. 2014 Jan;232(2):199-209.
18. Gatalica Z, Snyder C, Maney T, et al. Programmed cell death 1 (PD-1) and its ligand (PD-L1) in common cancers and their correlation with molecular cancer type. *Cancer Epidemiol Biomarkers Prev*, 2014; 23: 2965-70.
19. Gaule P, Smithy JW, Toki M, et al. A Quantitative Comparison of Antibodies to Programmed Cell Death 1 Ligand 1. *JAMA Oncol*. 2016 Aug 18. [Epub ahead of print]
20. Generali D, Bates G, Berruti A, et al. Immunomodulation of FoxP3⁺ regulatory T cells by the aromatase inhibitor letrozole in breast cancer patients. *Clin Cancer Res*, 2009; 15:1046-51.
21. Ghebeh H, Barhoush E, Tulbah A, et al. FoxP3⁺ Tregs and B7-H1/PD-1⁺ T lymphocytes co-infiltrate the tumor tissues of high risk breast cancer patients: implication for immunotherapy. *BMC Cancer*, 2008; 8:57.
22. Ghebeh H, Mohammed S, Al-Omair A, et al. The B7-H1 (PD-L1) T lymphocyte inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors. *Neoplasia*, 2006; 8:190-8.
23. Ingold Heppner B, Untch M, Denkert C, et al. Tumor-Infiltrating Lymphocytes: A Predictive and Prognostic Biomarker in Neoadjuvant-Treated HER2-Positive Breast Cancer. *Clin Cancer Res*. 2016 Dec 1;22(23):5747-5754.
24. Krieke B, van Kouwenhove M, Horlings H, et al. Gene expression profiling and histopathological characterization of triple negative/basal-like breast carcinomas. *Breast Cancer Res*, 2007; 9:R65.
25. Ladoire S, Arnould L, Apetoh L, et al. Pathologic complete response to neoadjuvant chemotherapy of breast carcinoma is associated with the disappearance of tumor-infiltrating FoxP3⁺ regulatory T cells. *Clin Cancer Res*, 2008; 14: 2413-20.
26. Ladoire S, Mignot G, Dabakuyo S, et al. In situ immune response after neoadjuvant chemotherapy predicts survival. *J Pathol*, 2011; 224: 389-400.
27. Lipson EJ, Forde PM, Hammers HJ, Emens LA, Taube JM, Topalian SL. Antagonists of PD-1 and PD-L1 in Cancer Treatment. *Semin Oncol*. 2015 Aug;42(4):587-600.
28. Loi S, Michiels S, Salgado R, et al. Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: the FinHER trial. *Ann Oncol*, 2014; 25:1544-50.
29. Loi S, Sirtaine N, Piette F, et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in a Phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. *J Clin Oncol*, 2013; 31:860-7.
30. Mahmoud SM, Paish EC, Powe DG, et al. Tumor infiltrating CD8⁺ lymphocytes predict clinical outcome in breast cancer. *J Clin Oncol*, 2011; 29:1949-55.
31. Martinet L, Garrido I, Filleron T, et al. Human solid tumors contain high endothelial venules: association with T- and B-lymphocyte infiltration and favorable prognosis in breast cancer. *Cancer Res*, 2011; 71:5678-87.
32. Moore OS, Foote FW. The relatively favorable prognosis of medullary carcinoma of the breast. *Cancer*. 1949 Jul;2(4):635-42.
33. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. *Nature Rev Cancer*, 2012; 12: 252-264.

34. Pitzalis C, Jones GW, Bombardieri M, Jones SA. Ectopic lymphoid-like structures in infection, cancer, and autoimmune disease. *Nature Rev Immunol*, 2014; 14:447-62.
35. Pruneri G, Vingiani A, Bagnardi V, et al. Clinical validity of tumor-infiltrating lymphocytes analysis in patients with triple-negative breast cancer. *Ann Oncol*. 2015 Nov 23. [Epub ahead of print]
36. Ridolfi RL, Rosen PP, Port A, et al. Medullary carcinoma of the breast: a clinicopathologic study with 10 year follow up. *Cancer*, 1977; 40:1365-85.
37. Rody A, Holtrich U, Pusztai L, et al. T cell metagene predicts a favorable prognosis in estrogen receptor-negative and Her2-positive breast cancers. *Breast Cancer Res*, 2009; 11:R15.
38. Rody A, Karn T, Liedtke C, et al. A clinically relevant gene signature in triple negative and basal-like breast cancer. *Breast Cancer Res*, 2011; 13:R97.
39. Salgado R, Denkert C, Demaria S, et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an international TILs Working Group 2014. *Ann Oncol*. 2015 Feb;26(2):259-71.
40. Savas P, Salgado R, Denkert C, et al. Clinical relevance of host immunity in breast cancer: from TILs to the clinic. *Nat Rev Clin Oncol*. 2016 Apr;13(4):228-41.
41. Schalper KA, Velcheti V, Carvajal D, et al. In situ PD-L1 mRNA expression is associated with increased TILs and better outcome in breast carcinomas. *Clin Cancer Res*, 2014; 20:2773-82.
42. Schalper KA, Velcheti V, Carvajal D, et al. In situ PD-L1 mRNA expression is associated with increased TILs and better outcome in breast carcinomas. *Clin Cancer Res*, 2014; 20: 2773-82.
43. Stanton SE, Adams S, Disis ML. Variation in the Incidence and Magnitude of Tumor-Infiltrating Lymphocytes in Breast Cancer Subtypes: A Systematic Review. *JAMA Oncol*. 2016 Oct 1;2(10):1354-1360.
44. Stanton SE, Disis ML. Clinical significance of tumor-infiltrating lymphocytes in breast cancer. *J Immunother Cancer*. 2016 Oct 18;4:59.
45. Taube JM, Anders RA, Young GD, et al. Colocalization of inflammatory response with B7-H1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. *Sci Transl Med*, 2012; 127ra37.
46. Thompson E, Taube JM, Elwood H, et al. The Immune Microenvironment of Breast Ductal Carcinoma in Situ. *Mod Pathol*. 2016 Mar;29(3):249-58.
47. Topalian SL, Taube JM, Anders RA, Pardoll DM. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. *Nat Rev Cancer*. 2016 May;16(5):275-87.
48. Velcheti V, Schalper KA, Carvajal DE, et al. Programmed death ligand-1 expression in non-small cell lung cancer. *Lab Invest*. 2014 Jan;94(1):107-16.
49. Wimberly H, Brown JR, Schalper KA, et al. PD-L1 expression correlates with tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy in breast cancer. *Cancer Immunol Res* 2015;3:326-32.